Research Project: Myeloperoxidase Promotes Persistent Fibrosis
basic biologic mechanisms
interstitial lung disease
Pulmonary fibrosis (PF) is a progressive fatal lung disease expected to increase dramatically due to post-COVID complications. In human disease and experimental models, it remains unclear what separates normal wound healing from progressive lung scarring and persistent disease. An enzyme called myeloperoxidase increases in PF and has been correlated with rapid deterioration of pulmonary fibrosis patients. Myeloperoxidase contributes to fibrosis in other major organ systems as well. Whether myeloperoxidase contributes to PF progression and prevents resorption of scar tissue is unknown. We will use laboratory tests and animal models of PF to determine the role of this enzyme in PF and determine if it is a potential target for treatment.